BGI Genomics Co., Ltd. (SHE:300676)

Market Cap	12.90B -33.0%
Revenue (ttm)	3.84B +3.4%
Net Income	-573.48M
EPS	-1.37
Shares Out	383.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,785,440
Open	34.60
Previous Close	34.92
Day's Range	33.28 - 35.10
52-Week Range	33.30 - 65.00
Beta	0.69
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About BGI Genomics

BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing,...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 3,580
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300676

Financial Performance

In 2025, BGI Genomics's revenue was 3.71 billion, a decrease of -4.18% compared to the previous year's 3.87 billion. Losses were -616.66 million, -31.69% less than in 2024.